Desktop 3D printers in the workplace: use, emissions, controls, and health.

Desktop three-dimensional (3D) printers are used in businesses, schools, and colleges, and are generally of an unenclosed design which may give rise to injuries or inhalation exposure to emissions of small particles (<1 µm) and volatile organic compounds (VOCs). The aim of this work was to explore the health risks related to the use of desktop 3D printers in workplaces in the United Kingdom. A digital survey on the use of desktop 3D printers was completed voluntarily and anonymously between February and June 2023, receiving 146 responses.

Detection of Prions in Wild Pigs (Sus scrofa) from Areas with Reported Chronic Wasting Disease Cases, United States.

Using a prion amplification assay, we identified prions in tissues from wild pigs (Sus scrofa) living in areas of the United States with variable chronic wasting disease (CWD) epidemiology. Our findings indicate that scavenging swine could play a role in disseminating CWD and could therefore influence its epidemiology, geographic distribution, and interspecies spread.

COVID-19-related lockdowns and changes in overweight and obesity, movement behaviours, diet quality, and health-related quality of life among regional Australian primary school children: A repeat cross-sectional study.

Background: During the coronavirus disease 2019 (COVID-19) pandemic, the Australian state of Victoria (in particular, its capital, Melbourne) experienced some of the longest lockdowns in the world.

Objective: This repeated cross-sectional study examined changes between March to June 2019 (pre-pandemic) and April to August 2022 (6 to 11 months following pandemic-related lockdowns) in overweight and obesity prevalence, physical activity, sedentary behaviour, sleep, diet quality, and health-related quality of life (HRQoL) among primary school children in north-east Victoria, Australia.

Methods: Height and weight were measured for Grade 2, 4, and 6 students in 2019 (3889 children) and 2022 (1816 children).

Optimal implementation of an Ontario nirsevimab program for respiratory syncytial virus (RSV) prophylaxis: Recommendations from a provincial RSV expert panel.

In June 2024, a group of 12 experts in the respiratory syncytial virus (RSV) field representing a cross-section of healthcare provider types who treat and care for pregnant individuals and infants, assembled to discuss the implementation of a broad infant prophylaxis program with nirsevimab in Ontario. To gain insight on potential best practices founded on the experiences of other jurisdictions, the meeting comprised a review of the 2023/2024 RSV season programs in Spain, France, and the United States that implemented nirsevimab prophylaxis. The impact of nirsevimab in reducing severe RSV disease among infants during the first RSV season was assessed including the implications on hospital resources and healthcare system costs.